Literature DB >> 2715499

In vitro colloid osmotic pressure of commonly used plasma expanders and substitutes: a study of the diffusibility of colloid molecules.

A R Webb1, S A Barclay, E D Bennett.   

Abstract

The rational choice of a plasma substitute for states of hypovolaemia depends partly on its colloid osmotic pressure (COP). We have measured the COP of 108 samples of plasma substitute across selectively permeable membranes which retain molecules greater than 10,000 dalton (COP10) and 50,000 dalton (COP50) the ratio COP50/COP10 providing a potential index of diffusibility of the smaller molecules across capillary membranes. 6% Hespan solution showed a particularly favourable COP50/COP10 ratio at 0.58 indicating a potential for good retention in the circulation whilst 3.5% Haemaccel showed a COP50/COP10 ratio of 0.18 indicating a potential for marked transcapillary diffusion, especially in states of capillary leak. In patients with normal capillary permeability both Gelofusine and Dextran 110 are likely to show adequate retention in the circulation with a COP50/COP10 ratio of 0.37 and 0.39 respectively. These are comparable to the retention of 4.5% human albumin (0.36) but all of the plasma substitutes tested, with the exception of Haemaccel, provided a higher COP across both membranes than 4.5% human albumin solution. An in vivo comparison of these plasma substitutes is required to confirm the advantages of macromolecular colloids in states of capillary leak.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2715499     DOI: 10.1007/BF00295988

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  11 in total

1.  Passage of dextran molecules across the blood-lymph barrier.

Authors:  G GROTTE
Journal:  Acta Chir Scand Suppl       Date:  1956

2.  [Colloid osmotic pressure of normal human blood, dextran and hydroxyethyl starch].

Authors:  H Yamasaki
Journal:  Masui       Date:  1973-11

3.  Estimation of equivalent pore radii of pulmonary capillary and alveolar membranes.

Authors:  A E Taylor; K A Gaar
Journal:  Am J Physiol       Date:  1970-04

4.  Crystalloid versus colloid in fluid resuscitation of patients with severe pulmonary insufficiency.

Authors:  L A Metildi; S R Shackford; R W Virgilio; R M Peters
Journal:  Surg Gynecol Obstet       Date:  1984-03

Review 5.  Synthetic plasma volume expanders--their pharmacology, safety and clinical efficacy.

Authors:  J M Mishler
Journal:  Clin Haematol       Date:  1984-02

6.  [Reply to W. L. Thompson's commentary (Infusionstherapie 4:56-62 1977) on G. Lindblad's and J. Falk's study on "Course of hydroxyethyl starch and dextran concentration in blood and liver of rabbits and the histopathological consequences of hydroxyethyl starch storage (Infusionstherapie 3:301-3 1976)].

Authors: 
Journal:  Infusionsther Klin Ernahr       Date:  1978-04

7.  Incidence, pathomechanism and prevention of dextran-induced anaphylactoid / anaphylactic reactions in man.

Authors:  H Hedin; W Richter; K Messmer; H Renck; K G Ljungström; H Laubenthal
Journal:  Dev Biol Stand       Date:  1980

8.  Colloid osmotic pressure and fluid resuscitation with hetastarch, albumin, and saline solutions.

Authors:  M T Haupt; E C Rackow
Journal:  Crit Care Med       Date:  1982-03       Impact factor: 7.598

9.  The short-term effects of increasing plasma colloid osmotic pressure in patients with noncardiac pulmonary edema.

Authors:  W J Sibbald; A A Driedger; G A Wells; M L Myers; M Lefcoe
Journal:  Surgery       Date:  1983-05       Impact factor: 3.982

10.  [Haemaccel 35: adverse reactions in a multicentric, prospective study].

Authors:  K H Weis
Journal:  Anaesthesist       Date:  1983-10       Impact factor: 1.041

View more
  11 in total

1.  A narrow range, medium molecular weight pentastarch reduces structural organ damage in a hyperdynamic porcine model of sepsis.

Authors:  A R Webb; R F Moss; D Tighe; M G Mythen; N al-Saady; A E Joseph; E D Bennett
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

Review 2.  Intravenous volume replacement: which fluid and why?

Authors:  L Huskisson
Journal:  Arch Dis Child       Date:  1992-05       Impact factor: 3.791

Review 3.  Colloid volume expanders. Problems, pitfalls and possibilities.

Authors:  J S Roberts; S L Bratton
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

4.  Small-volume resuscitation from hemorrhagic shock with polymerized human serum albumin.

Authors:  Catalina Messmer; Ozlem Yalcin; Andre F Palmer; Pedro Cabrales
Journal:  Am J Emerg Med       Date:  2011-11-17       Impact factor: 2.469

5.  Synthesis, biophysical properties and pharmacokinetics of ultrahigh molecular weight tense and relaxed state polymerized bovine hemoglobins.

Authors:  Paul W Buehler; Yipin Zhou; Pedro Cabrales; Yiping Jia; Guoyong Sun; David R Harris; Amy G Tsai; Marcos Intaglietta; Andre F Palmer
Journal:  Biomaterials       Date:  2010-02-10       Impact factor: 12.479

Review 6.  Blood substitutes: evolution from noncarrying to oxygen- and gas-carrying fluids.

Authors:  Pedro Cabrales; Marcos Intaglietta
Journal:  ASAIO J       Date:  2013 Jul-Aug       Impact factor: 2.872

7.  Delaying blood transfusion in experimental acute anemia with a perfluorocarbon emulsion.

Authors:  Pedro Cabrales; Juan Carlos Briceño
Journal:  Anesthesiology       Date:  2011-04       Impact factor: 7.892

8.  Tissue oxygenation after exchange transfusion with ultrahigh-molecular-weight tense- and relaxed-state polymerized bovine hemoglobins.

Authors:  Pedro Cabrales; Yipin Zhou; David R Harris; Andre F Palmer
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-01-08       Impact factor: 4.733

9.  Crystalloid or colloid for resuscitation. Are we any the wiser?

Authors: 
Journal:  Crit Care       Date:  1999       Impact factor: 9.097

10.  Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials.

Authors:  Christian J Wiedermann; Stefan Dunzendorfer; Luigi U Gaioni; Francesco Zaraca; Michael Joannidis
Journal:  Crit Care       Date:  2010-10-28       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.